YSYuki Segi

Yuki Segi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuki Segi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preoperative Risk Classification for Early Recurrence After Curative-Intent Resection of Perihilar Cholangiocarcinoma: A Single-Center Retrospective Study

    by Yu Fujimura, Naohisa Kuriyama, Yuki Segi, Haruna Komatsubara, Kazuyuki Gyoten, Takahiro Ito, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, et al.

    Background/Objectives: Early recurrence (ER) after curative-intent resection of perihilar cholangiocarcinoma (PHC) is associated with poor prognosis. However, simple preoperative predictors remain insufficiently defined. This study aimed to identify preoperative factors associated with ER and explore a risk classification. Methods: We retrospectively analyzed 108 patients who underwent curative-intent resection for PHC at a single institution between 2007 and 2023. ER was defined as recurrence within 1 year after surgery. Cox proportional hazards regression was used to identify associated factors. Results: ER occurred in 24 patients (22.2%). Multivariable analysis identified younger age (hazard ratio [HR] = 0.942), higher carcinoembryonic antigen (CEA; HR = 1.115), higher carbohydrate antigen 19-9 (CA19-9; HR = 1.001), and higher neutrophil-to-lymphocyte ratio (NLR; HR = 1.404) as factors associated with ER. In an exploratory classification, one point was assigned for age < 61 years, CEA ≥ 5.4 ng/mL, CA19-9 ≥ 89.4 U/mL, and NLR ≥ 2.037. Among 105 patients with complete data, the estimated 1-year recurrence rate was 70.0% in patients with 3–4 points (n = 10), versus 17.4% in those with 0–2 points (n = 95; p < 0.001). Bootstrap analysis suggested optimism in the score’s apparent discrimination when cutoff optimization was considered (optimism-corrected C-index, 0.668). Conclusions: Age, CEA, CA19-9, and NLR were associated with ER after PHC resection. The exploratory classification requires external validation before clinical use.

  • Open Access

    Long-Term Outcomes of Anatomical and Biological Borderline Resectable Pancreatic Ductal Adenocarcinoma After Gemcitabine/S-1-Based Neoadjuvant Chemoradiotherapy

    by Haruna Komatsubara, Shugo Mizuno, Daisuke Noguchi, Naohisa Kuriyama, Aoi Hayasaki, Yuki Segi, Kazuyuki Gyoten, Takahiro Ito, Yusuke Iizawa, Takehiro Fujii, et al.

    Background/Objectives: Oncological outcomes in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) remain unclear. This long-term observational study evaluated these outcomes in patients with BR-PDAC treated with a consistent neoadjuvant chemoradiotherapy (CRT) regimen and explored host-related prognostic markers. Methods: We retrospectively analyzed 206 patients with PDAC who received neoadjuvant gemcitabine plus S-1 with concurrent radiotherapy between 2011 and 2022. Biological BR was defined as anatomically resectable disease with an initial carbohydrate antigen 19-9 (CA19-9) level ≥500 U/mL. Anatomical BR was subdivided into portal venous involvement (BR-PV) and arterial involvement (BR-A). Outcomes were compared according to resectability and surgical resection, with resectable (R) patients as a reference. Prognostic factors among resected BR patients were assessed using multivariable Cox regression analysis. Results: The median follow-up was 62.5 months. Resection rates were 85.7%, 83.3%, 69.8%, and 55.6% for R, biological BR, BR-PV, and BR-A, respectively. Although the resection rate of biological BR was similar to that of R, its survival did not differ significantly from that of anatomical BR. Across all BR subtypes, surgical resection was associated with longer overall survival. Among resected patients, the post-CRT neutrophil-lymphocyte-to-monocyte ratio (NL/M), a peripheral blood cell index, was associated with overall survival (hazard ratio 1.020, p = 0.009). Patients with a high post-CRT NL/M had poorer prognosis than those with a low NL/M (p = 0.001). Conclusions: Biological and anatomical BR-PDAC showed no significant difference in long-term survival after neoadjuvant CRT, and surgical resection was associated with longer survival across BR subtypes. Post-CRT NL/M was associated with overall survival after resection and may serve as a potential host-related prognostic marker, although further validation is needed.

  • Open Access

    Long-Term Outcomes of a Multidisciplinary Treatment Strategy Using Neoadjuvant Gemcitabine Plus S-1 Based on Anatomical Resectability Classification and Lymph Node Status in Patients with Perihilar Cholangiocarcinoma

    by Naohisa Kuriyama, Shugo Mizuno, Yuki Segi, Haruna Komatusbara, Kazuyuki Gyoten, Takahiro Ito, Aoi Hayasaki, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, et al.

    Objectives: The long-term impact of neoadjuvant chemotherapy (NAC) based on anatomical resectability for perihilar cholangiocarcinoma (PHC) remains unclear. We evaluated the mature long-term outcomes of our multidisciplinary treatment strategy based on anatomical resectability classification and regional lymph node (LN) status using gemcitabine plus S-1 (NAC-GS). Methods: Between September 2010 and August 2021, 110 consecutive PHC patients were classified as resectable (R; n = 47), borderline resectable (BR; n = 38), or unresectable locally advanced (UR-LA; n = 25) according to our anatomical resectability classification. NAC-GS was administered to patients with clinically positive LN metastasis and to BR and UR-LA patients. Long-term overall survival (OS), recurrence-free survival (RFS), and prognostic factors were evaluated. Results: NAC-GS was administered to 72 patients (65.5%). Curative-intent resection was achieved in 40 (85.1%), 25 (65.8%), and 6 (24.0%) patients in the R, BR, and UR-LA groups, respectively. In the overall cohort, anatomical resectability significantly stratified OS (p = 0.032). However, among patients who underwent curative-intent resection, OS and RFS were comparable across the three resectability groups. Those receiving NAC-GS showed favorable long-term survival despite having more advanced disease characteristics; however, this comparison was limited to selected patients who ultimately proceeded to surgery. Multivariable analysis identified preoperative serum carcinoembryonic antigen ≥5.5 ng/mL (HR: 3.174, p = 0.003), non-adjuvant therapy (HR: 2.222, p = 0.023) and pathological T4 (HR: 2.397, p = 0.037) as independent predictors of poor survival. Conclusions: Anatomical resectability was associated with long-term prognosis and the likelihood of achieving curative-intent resection. Selected patients who ultimately underwent curative-intent resection after NAC-GS showed favorable long-term outcomes; however, these findings do not establish a survival benefit of NAC-GS over upfront surgery. Prospective multi-institutional validation is warranted.

  • Open Access

    Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy

    by Aoi Hayasaki, Shugo Mizuno, Benson Kaluba, Yuki Segi, Haruna Komatsubara, Tatsuya Sakamoto, Koki Maeda, Toru Shinkai, Takahiro Ito, Kazuyuki Gyoten, et al.